Intchains Group
ICG
BIGG DIGITAL ASSETS INC
BBKCF
NEPTUNE DIGITAL ASSETS CORP
NPPTF
Bitdeer Technologies
BTDR
FRMO CORP
FRMO
US Stock MarketDetailed Quotes
SLRN Acelyrin
- 3.150
- -0.070-2.17%
Close Dec 20 16:00 ET
- 3.150
- 0.0000.00%
Post 16:13 ET
316.03MMarket Cap-1.19P/E (TTM)
3.250High3.105Low956.11KVolume3.180Open3.220Pre Close3.01MTurnover1.59%Turnover RatioLossP/E (Static)100.33MShares8.88552wk High0.60P/B189.70MFloat Cap3.10552wk Low--Dividend TTM60.22MShs Float29.880Historical High--Div YieldTTM4.50%Amplitude3.105Historical Low3.152Avg Price1Lot Size
Acelyrin News
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $5
Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales Projections
Acelyrin Price Target Lowered to $5 From $6 at Morgan Stanley
ACELYRIN Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
Express News | Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance
Express News | ACELYRIN Inc Shares Down 16.5% Premarket After Co's Eye Drug Fails in Study, CFO Resigns
ACELYRIN, INC. (SLRN) Receives a Buy From Piper Sandler
Express News | HC Wainwright & Co. Reiterates Neutral on Acelyrin, Maintains $8 Price Target
Acelyrin Analyst Ratings
Optimistic Outlook for ACELYRIN as Focus Shifts to Promising TED Treatment
Hold Rating for ACELYRIN, INC. Amid Izokibep Trial Setback and Focus on Lonigutamab Development
Express News | ACELYRIN Inc : Jefferies Cuts Target Price to $8 From $14
Acelyrin Says Uveitis Treatment Trial Fails to Meet Primary Endpoint; Shares Fall After Hours
Acelyrin Finance Chief Gil Labrucherie to Exit
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.